Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn’s Disease

Figure 5

The levels of LPS and BG are decreased with IFX. Sixteen A-CD patients received IFX at a dose of 5 mg/kg body weight at weeks 1, 2, and 6. The sera were collected 12 weeks after IFX therapy and analyzed for LPS and BG. (a) The levels of LPS were significantly decreased () as compared with those before IFX treatment. (b) The levels of BG were significantly decreased () as compared with those before IFX treatment.

(a)

(b)